IPP Bureau
14.9 million excess deaths associated with the Covid-19 pandemic in 2020 and 2021
By IPP Bureau - May 05, 2022
The report has estimated 4.74 million deaths for India in 2020 and 2021,
HPRA completes audit of Biocon Biologics New mAbs drug substance facility
By IPP Bureau - May 04, 2022
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
Eugia Pharma receives USFDA approval for Bortezomib
By IPP Bureau - May 04, 2022
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Alkem launches Innohaler for asthma & COPD patients
By IPP Bureau - May 04, 2022
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Scipio bioscience announces its revolutionary Asteria single-cell RNA-seq kit
By IPP Bureau - May 04, 2022
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
.jpg "Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore")
Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore
By IPP Bureau - May 04, 2022
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
New study links gut microbiota strains with more severe strokes and poorer post-stroke recovery
By IPP Bureau - May 04, 2022
The study, presented at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated with poorer neurological recovery from ischaemic stroke both in the acute phase (24 hours) and after three months
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets including India
By IPP Bureau - May 04, 2022
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
India’s Drugs Controller General green lights trial of TRIA heart valve
By IPP Bureau - May 04, 2022
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
Aleor Dermaceuticals receives USFDA approval for Docosanol Cream
By IPP Bureau - May 04, 2022
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA
Kokilaben Dhirubhai Ambani Hospital launches third da Vinci robotic surgical system
By IPP Bureau - May 04, 2022
It is the first hospital in the country to achieve the significant milestone of completing over 2600 robotic surgeries for treating patients with prostate, kidney and urinary bladder cancer
Gland launches Bortezomib in the US market
By IPP Bureau - May 04, 2022
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Foundation S: Sanofi’s new philanthropic spearhead
By IPP Bureau - May 04, 2022
Foundation S will incorporate as its cornerstone initiative the former Sanofi Espoir Foundation’s ‘My Child Matters’ program in childhood cancer
Mylab launches RT-PCR test for Ankylosing Spondylitis ahead of the World AS Day
By IPP Bureau - May 04, 2022
This RT-PCR diagnostic kit helps in diagnosis of AS by detecting HLAB27 gene
GOQii launches first of its kind one-stop solution for Diabetes care in India
By IPP Bureau - May 04, 2022
An Integrated programme comprising GOQii device, Glucometer – Contour Plus+1 from Ascensia Diabetes Care India and personalised diabetes coaching
